MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 5:158-161, (2005)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.5.3.5
This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasbi, A.
Right arrow Articles by George, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasbi, A.
Right arrow Articles by George, S. R.

Viewpoint

A G Protein–Coupled Receptor For Estrogen: The End Of The Search?

Ahmed Hasbi1, Brian F. O’Dowd1,2 and Susan R. George1,2,3

1 Departments of Pharmacology and
2 Medicine,
3 University of Toronto and the Center for Addiction and Mental Health, Toronto, Ontario, Canada

SUMMARY

The effects of estrogen on responsive cells and organismic development have long been known and well documented. Estrogen binds to the estrogen receptor, a dimer of the complex translocates to the nucleus, binds specific DNA elements and regulates the transcription of particular genes, a process that takes some time to achieve. One of the curious findings of intense estrogen research—that some estrogen-dependent effects appear to occur immediately—has led to the conclusion that quick responses are mediated by an estrogen binding protein(s) in the cytoplasm or located at the plasma membrane. Hasbi et al. chart the course through which several characterized estrogen binding proteins (not necessarily sharing sequence similarity beyond the estrogen binding domain) were discovered, including most notably, the orphan G protein–coupled receptor GPR30. And what is to be made of differing accounts of GPR30’s intracellular whereabouts?

Estrogen is a steroid hormone involved in the regulation of a wide array of processes that include reproduction, sexual development, behavior, stress responses, bone integrity, neuroprotection, and cardiovascular health (1, 2). These effects take place in the central nervous system as well as in targeted tissues, such as the uterus and mammary gland (3).

In early studies, estrogen was considered a metabolic cofactor until the discovery of its first specific receptor, the estrogen receptor (ER), from extracts of rat uterus and vagina (4). The ER belongs to the steroid hormone nuclear receptor superfamily [reviewed in (2)]. Upon activation by their respective hormones, the members of this superfamily act as transcriptional factors modulating the expression of different genes. The ER was then named ER{alpha} when a second estrogen receptor, named ERß, was isolated (5). ER{alpha} and ERß mediate most of the estrogen-induced transcriptional effects; the actions of these receptors, however, are not redundant, but rather, complementary (2, 3). Another ER-related protein, named ER{gamma}, has also been discovered (6).

The binding of estrogen triggers conformational changes in the ERs including their phosphorylation on serine and tyrosine residues, dissociation from the 90-kDa heat shock protein (hsp90), and subsequent ER dimerization. The ER{alpha} and ERß receptors homodimerize, and can also heterodimerize to generate distinct functions. The receptor dimers interact with other transcriptional cofactors and with the estrogen response element (ERE), a specific regulatory DNA sequence present in the promoter of target genes (2, 3). The resulting suppression or enhancement of gene expression (leading to protein synthesis) allows the estrogen-mediated physiological responses to take place within hours after exposure to estrogen (2, 3). For these "genomic" effects, estrogen seems to directly modulate DNA using its ERs, and this process does not involve the second messenger signaling pathways.

Many estrogen-regulated effects, however, cannot be explained by this scheme of action. Some estrogen-targeted genes do not possess an apparent ERE (3), and many of the effects of estrogen occur rapidly within seconds to minutes (2, 3) and involve a variety of intracellular second messenger signaling pathways (7–9). Reports have suggested that these "rapid" and "nongenomic" events were mediated via ER{alpha} and ERß (10, 11); however, growing evidence suggests the involvement of plasma membrane receptors, and especially G protein–coupled receptors (GPCRs).

As early as 1977, specific binding sites for estrogen were reported on the outer surface of isolated endometrial cells (12), but because of the difficulties in isolating and characterizing these sites, the existence of plasma membrane–associated ERs has remained controversial for over three decades. Also, the interests of researchers were focused more on estrogen-initiated genomic actions than on the nongenomic ones, which may have retarded progress in the elucidation of the membrane-related actions of estrogen.

In fact, a growing body of functional, biochemical and pharmacological evidence clearly suggest the presence of plasma membrane-associated estrogen receptors. One of these receptors was recently identified by different teams to be GPR30, an orphan GPCR (13, 14). Other membrane-associated estrogen receptors (mERs) have also been described.

A report that 17ß-estradiol (E2) activated the mitogen-activated protein kinase (MAPK) pathway in untransfected CHO-K1 and COS7 cells as well as in Rat2-fibroblasts (3), suggested that these cell lines may endogenously express an unidentified mER (3). It was also reported that E2 activated the serine–threonine protein kinase B-Raf and the MAPK/ERK (extracellular-regulated kinase) pathway in cerebral cortical explants derived from ER{alpha}–/– as well as from wild-type mice (8). Selective agonists to ER{alpha} and ERß were unable to elicit ERK phosphorylation, and their antagonist ICI 182,780 was unable to block these actions, suggesting the presence of a new mER in mouse brain (8).

Another study showed that E2 altered µ opioid and {gamma}-amino butyric acid (GABA) mediated neurotransmission rapidly in hypothalamic neurons via a mechanism involving protein kinase C (15). These effects were mimicked by a membrane-impermeable complex of E2 with albumin (E2-BSA) and separately by a new selective modulator of E2 termed STX (a diphenylacrylamide), which is unable to bind to ER{alpha} or ERß, suggesting that the actions of E2 were mediated by a novel, Gq-coupled mER (15). E2 also binds to a specific receptor that activates protein kinase A (PKA), resulting in the µ-opioid receptor uncoupling from K+ channels (16). The estrogen-induced modulation of neuronal excitability has also been demonstrated for different GPCRs in ß-endorphin, dopamine, and GABAergic neurons (17), as well as for acetylcholine-induced responses in GT1-7 cells involving a mER visualized on the cell surface through fluorescein-conjugated E2-BSA (18).

A specific and unique mER, referred to as ER-X, was also characterized and shown to be developmentally regulated and distinct from ER{alpha} and ERß (19). Its pharmacological profile was different from that of ER{alpha} and ERß, with some characteristics opposite to those shown for these receptors. For example, the association of hsp90 is required for the inactive steady state of ER{alpha}, whereas, ER-X needs to be associated with hsp90 to mediate MAPK/ERK activation (3, 19). A heterodimeric estrogen-binding protein, named the putative ER (pER), demonstrated a high subnanomolar affinity for E2 but was unable to bind other steroids, such as synthetic estrogens or antiestrogen. Depending on the cells examined, pER was localized at the plasma membrane and/or nuclear membrane, or in the cytoplasm and/or nucleus (20). Other new but unidentified mERs have been reported based on their ability to transduce functional responses, such as K+ channel activation, adenosine 3',5'-monophosphate (cyclic AMP, cAMP) accumulation, and calcium mobilization (Table 1Go) [reviewed in (2, 3)].


View this table:
[in this window]
[in a new window]
  		Table 1. Putative Membrane Estrogen Receptors (mER), Their Distribution, and Their Defining Characteristics
 
Recently, different groups identified and characterized an orphan GPCR, GPR30, as a new estrogen-receptor involved in the rapid actions elicited by estrogen (13, 14). In late 1990s, we and others independently cloned GPR30 (21–23). Its deduced aminoacid sequence showed a heptahelical-serpentine transmembrane structure—one of the characteristics shared by all GPCR superfamily members. Based on its structural similarity with receptors that bind chemokines and angiotensin II, the endogenous GPR30 ligand was thought to be a peptide; however, when tested, neither chemotactic peptides nor angiotensin II or angiotensin VI bound to GPR30 (3). GPR30 is widely distributed in different tissues including heart, breast, lung, CNS, vascular endothelium, and leukocytes (2, 23), and in ER-positive tumor cell lines (24).

Because GPR30 is expressed in tissues and in tumors that respond to estrogen, and because G-protein inhibition alters the second messenger pathways elicited by estrogen in these tissues and tumors, different groups focused on the participation of GPR30 in rapid-onset estrogen-mediated actions. Thus, estrogen was shown to induce adenylyl cyclase (AC) and MAPK activation in MCF-7 breast cancer cells that express GPR30, but not in MDA-MB 231 cells that express ERß but not GPR30 (7, 25). These effects, however, were restored in MDA-MB 231 cells transfected with GPR30 cDNA (7, 25), and involved Gß{gamma}-subunits and downstream activation of a Src-related tyrosine kinase. ER antagonists including ICI 182,780 were able to induce ERK activation, suggesting that this estrogen-induced action was GPR30-mediated and was independent of ER{alpha} and ERß (7, 25).

GPR30 also mediates increased c-fos expression elicited by E2 or by the phytoestrogens genistein and quercitin, in breast cancer cells (26). Furthermore, increased c-fos expression was repressed in GPR30-expressing SKBR3 cells transfected with an antisense oligonucleotide against GPR30, and was reconstituted in GPR30-deficient MDA-MB 231 and BT-20 breast cancer cells transfected with GPR30 cDNA (26). Increased c-fos expression was sensitive to Gß{gamma}– and pertussis toxin (PTX), and involved the tyrosine kinase activities of Src and the epidermal growth factor (EGF) receptor (26). Specifically, the ability of the agonists to increase c-fos expression in SKBR3 cells was completely abrogated when cells were pretreated with either PTX or the Src family tyrosine kinase inhibitor PP2 (26).

Recently, GPR30 was definitively identified as a mER by two different groups (13, 14). Thomas et al. culminated their investigations of this receptor by identifying it as a high-affinity, saturable, displaceable, single binding site for E2 in membranes from breast cancer SKBR3 cells (13). They had previously established that these cells do not express ER{alpha} or ERß but do endogenously express GPR30. These authors also showed that, unlike untransfected cells, Human Embryonic Kidney 293 (HEK 293) cells transfected with GPR30 cDNA possess a high-affinity binding site for estrogen, which, when activated, led to the activation of a stimulatory G protein and subsequent activation of AC (26). Taken together their results showed that GPR30 was a plasma membrane-associated GPCR, mediating estrogen-elicited rapid responses.

Revankar et al. showed that GPR30 activation by estrogen led to intracellular calcium mobilization and phosphatidylinositol- 3,4,5-trisphosphate accumulation in the nucleus (14). The most intriguing part of this study, however, was the finding that GPR30 was exclusively localized in the endoplasmic reticulum—results confirmed by differentially tagged GPR30 constructs and fluorescent estrogen derivatives. This differs from what was observed by Thomas et al. (13) and by others, who have observed GPR30 localized at the plasma membrane. This finding by Revankar et al. (14) also is in contrast with the plasma membrane-association and functionality usually described for GPCRs. It is a fact that processing is a critical step for GPCRs to exit from endoplasmic reticulum and to traffic to the plasma membrane. Some of these receptors, such as the GABAB receptor, must to be associated with other GPCRs or chaperone proteins to reach the plasma membrane. Nevertheless, and taking into account all the processing steps, the finding by Revankar et al. (14), if confirmed, would make GPR30 unique, or at least confirm GPR30 as the first GPCRs that functions in a non-nuclear intracellular compartment.

We are faced with a growing body of compelling evidence for the presence of ERs that are completely different from the well-known ERs that have nuclear functions. These newly identified receptor(s) mediate estrogen-elicited rapid responses, and control different physiological, and probably, pathophysiological actions of estrogen. Accumulating evidence clearly identifies GPR30 as one of these receptors, responsible for rapid estrogen-elicited responses in different cell lines, whether it is localized at the plasma membrane or in intracellular compartments. Is GPR30, functioning as "the membrane receptor for estrogen," responsible for all the rapid nongenomic responses of estrogen or are there different mERs representing a new subfamily of plasma membrane estrogen receptors? Further characterization of GPR30 and other putative mERs, their (sub)cellular and tissue distribution, as well as their mode of action, will contribute to better understanding of the complexity of estrogen receptor-mediated signal transduction in relation to the wide range of physiological roles played by estrogen. It may also help to clearly distinguish estrogen-elicited functions (genomic vs nongenomic), and may open new therapeutic windows for the drug discovery process to target the pathological as well as beneficial effects linked to estrogen and its receptors.


Susan R. George, MD, is a Professor of Medicine and Pharmacology at the University of Toronto, a Senior Scientist at the Center for Addiction and Mental Health and a clinical endocrinologist at the Toronto General Hospital, University Health Network, Toronto, Canada. She holds a Canada Research Chair in Molecular Neuroscience and her research interests include the biology of G protein coupled receptors (GPCRs). Together with Brian O’Dowd, PhD, Professor of Pharmacology at the University of Toronto and Senior Scientist at the Center for Addiction and Mental Health, their research laboratories focus on the receptors for neurotransmitters such as dopamine and opioids, receptor function and oligomerization, structure–activity relationships and the discovery of novel genes encoding GPCRs.


Ahmed Hasbi, PhD, is a post-doctoral fellow in this group in the Department of Pharmacology at the University of Toronto with a particular interest in opioid and oxytocin receptors and has a current focus in elucidating the complexities of opioid receptor heterooligomerization.

References

  1. Hewitt, S.C., Deroo, B.J., and Korach, K.S. A new mediator for an old hormone? Science 307, 1572–1573 (2005). Commentary accompanying one of the articles that identified GPR30 to be an estrogen receptor.[Abstract/Free Full Text]
  2. Filardo, E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer. J. Steroid Biochem. Mol. Biol. 80, 231–238 (2002). Reporting estrogen activation of GPR30 leading to EGFR transactivation.[CrossRef][Medline]
  3. Toran-Allerand, C.D. A plethora of estrogen receptors in the brain: Where will it end? Endocrinology 145, 1069–1074 (2004). Review highlighting properties of classical and putative membrane-associated estrogen receptors.[Abstract/Free Full Text]
  4. Jenkens, E.V. and Desombre, E.R. Estrogen receptor interactions. Science 182, 126–134 (1973).[Abstract/Free Full Text]
  5. Mosselman, S., Polman, J., and Dijkema, R. ERß: Identification and characterization of a novel human estrogen receptor. FEBS Letters 392, 49–53 (1996).[CrossRef][Medline]
  6. Hawkins, M.B., Thornton, J.W., Crews, D., Skipper, J.K., Dotte, A., Thomas, P. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc. Natl. Acad. Sci. U.S.A. 97, 10751–107556 (2000).[Abstract/Free Full Text]
  7. Filardo, E.J., Quinn, J.A., Frackelton, A.R. Jr., and Bland, K.I. Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endo. 16, 70–84 (2002).[Abstract/Free Full Text]
  8. Singh, M., Setalo, G. Jr., Guan, X., Frail, D.E., and Toran-Allerand, C.D. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-{alpha} knock-out mice. J. Neurosci. 20, 1694–1700 (2000).[Abstract/Free Full Text]
  9. Nakhla, A.M., Leonard, J., Hryb, D.J., and Rosner, W. Sex hormone-binding globulin receptor signal transduction proceeds via a G-protein. Steroids 64, 213–216 (1999).[CrossRef][Medline]
  10. Razandi, M., Pedram, A., Park, S.T., and Levin, E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278, 2701–2712 (2003).[Abstract/Free Full Text]
  11. Wade, C.B., Robinson, S., Shapiro, R.A., and Dorsa, D.M. Estrogen receptor (ER){alpha} and ERß exhibit unique pharmacologic properties when coupled to activation of mitogen-activated protein kinase pathway. Endocrinology 142, 2336–2342 (2001).[Abstract/Free Full Text]
  12. Pietras, R.J. and Szego, C.M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265, 69–72 (1977).[CrossRef][Medline]
  13. Thomas, P., Pang, Y., Filardo, E.J., and Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146, 624–632 (2005). The latest findings from this group on GPR30 as a membrane-associated, G-protein coupled estrogen receptor, discussed in this Viewpoint.[Abstract/Free Full Text]
  14. Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B., and Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625–1630 (2005). Report of GPR30 identified as an estrogen receptor, and the first description of GPR30 as a functioning intracellular GPCR, described in this Viewpoint.[Abstract/Free Full Text]
  15. Qui, J., Bosch, M.A., Tobias, S.C., Grandy, D.K., Scanlan, T.S., Rønnekleiv, O.K. and Kelly, M.J. Rapid signaling in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J. Neurosc. 23, 9540–9529 (2003).
  16. Lagrange, A.H., Rønnekleiv, O.K., and Kelly, M.J. Modulation of G protein- coupled receptors by an estrogen receptor that activates protein kinase A. Mol. Pharmacol. 51, 605–612 (1997).[Abstract/Free Full Text]
  17. Kelly, J.M., Qui, J., and Rønnekleiv, O.K. Estrogen modulation of G-protein- coupled receptor activation of potassium channels in the central nervous system. Ann. N. Y. Acad. Sci. 1007, 6–16 (2003). Review of estrogen modulation of neuronal excitability by membrane-associated receptors and multiple cellular signaling pathways.[CrossRef][Medline]
  18. Morales, A., Díaz, M., Ropero, A.B., Nadal, A., and Alonso, R. Estradiol modulates acetylcholine-induced Ca2+ signals in LHRH-releasing GT1-7 cells through a membrane binding site. Eur. J. Neurosci. 18, 2505–2514 (2003).[CrossRef][Medline]
  19. Toran-Allerand, C.D., Guan, X., MacLusky, N.J., Horvath, T.L., Diano, S., Singh, M., Connolly, E.S. Jr., Nethrapalli, I.S., and Tinnikov, A.A. ER-X: A novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J. Neurosci. 22, 8391–8401 (2002).[Abstract/Free Full Text]
  20. Rao B.R. Isolation and characterization of an estrogen binding protein which may integrate the plethora of estrogenic avtions in non-reproductive organs. J. Steroid Biochem. Mol. Biol. 65, 3–41 (1998).[CrossRef][Medline]
  21. O’Dowd, B.F., Nguyen, T., Marchese, A., Cheng, R., Lynch, K.R., Heng, H.H., Kolakowski, L.F. Jr., George, S.R. Discovery of three novel G-protein- coupled receptor genes. Genomics 47, 310–313 (1998).[CrossRef][Medline]
  22. Takada Y., Kato C., Kondo S., Korenaga R., and Ando J. Encoding of cDNAs encoding G-protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem. Biophys. Res. Commun. 240, 737–741 (1997).[CrossRef][Medline]
  23. Kvingedal A.M., and Smeland E.B. A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. FEBS Lett. 407, 59–62 (1997).[CrossRef][Medline]
  24. Ylikomi, T., Vienonen, A., and Ahola, T.M. G protein-coupled receptor 30 down-regulates cofactor expression and interferes with the transcriptional activity of glucocorticoid. Eur. J. Biochem. 271, 4159–4168 (2004).[Medline]
  25. Filardo, E.J., Quinn, J.A., Bland, K.I., and Frackelton, A.R., Jr. Estrogen-induced activation of ERK-1 and ERK-2 recquires the G-protein-coupled receptor homolog, GPR30, and occurs via trans-activation of epidermal growth factor receptor through release of HB-EGF. Mol. Endo. 14, 1649–1660 (2000).[Abstract/Free Full Text]
  26. Maggiolini, M., Vivacqua, A., Fasanella, G. et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17-ß-estradiol and phytoestrogens in breast cancer cells. J.Biol. Chem. 279, 27008–27016 (2004).[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 EndocrinologyHome page
L. Albanito, D. Sisci, S. Aquila, E. Brunelli, A. Vivacqua, A. Madeo, R. Lappano, D. P. Pandey, D. Picard, L. Mauro, et al.
Epidermal Growth Factor Induces G Protein-Coupled Receptor 30 Expression in Estrogen Receptor-Negative Breast Cancer Cells
Endocrinology, August 1, 2008; 149(8): 3799 - 3808.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
V. M. Miller and S. P. Duckles
Vascular Actions of Estrogens: Functional Implications
Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. D. Feldman and R. Gros
Choreographing the Rapid Vascular Effects of Estrogen: Sorting Out the Partners and the Steps
Hypertension, June 1, 2007; 49(6): 1222 - 1224.
[Full Text] [PDF]

Home page
 HypertensionHome page
M. R. Meyer, E. Haas, and M. Barton
Gender Differences of Cardiovascular Disease: New Perspectives for Estrogen Receptor Signaling
Hypertension, June 1, 2006; 47(6): 1019 - 1026.
[Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. D'Astous, P. Mendez, M. Morissette, L. M. Garcia-Segura, and T. Di Paolo
Implication of the Phosphatidylinositol-3 Kinase/Protein Kinase B Signaling Pathway in the Neuroprotective Effect of Estradiol in the Striatum of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mice
Mol. Pharmacol., April 1, 2006; 69(4): 1492 - 1498.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasbi, A.
Right arrow Articles by George, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasbi, A.
Right arrow Articles by George, S. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.